Royal Jelly Lyophilized (Apis mellifera)

Royal jelly lyophilized is a freeze-dried secretion from worker honeybees (Apis mellifera) concentrated in major royal jelly proteins (MRJPs), 10-hydroxy-2-decenoic acid (10-HDA), and royalactin. These bioactive compounds interact with immune signaling pathways and exhibit antimicrobial and cytotoxic properties primarily demonstrated in vitro and in animal models.

Origin & History

Royal Jelly Lyophilized is a freeze-dried form of royal jelly, a nutrient-rich secretion produced by hypopharyngeal and mandibular glands of worker honeybees (Apis mellifera) to feed queen bee larvae and adult queens. The lyophilization process removes water content to 3.5-4.8%, preserving the composition of proteins (43.6-50.3% dry basis), lipids (3-8.6%), carbohydrates (24-33%), and bioactive compounds.

Historical & Cultural Context

The research dossier provides no information about traditional or historical uses of royal jelly. No traditional medicine systems or historical applications are documented in the available data.

Health Benefits

• Immunomodulation through major royal jelly proteins (MRJP2/MRJP3) - based on biochemical analysis only, no clinical trials available
• Anti-microbial effects attributed to protein components - mechanistic evidence only, no human studies found
• Anti-tumor activity suggested by component analysis - no clinical evidence provided in research
• Anti-inflammatory and anti-allergic properties via MRJP3 - biochemical pathway identified, clinical trials lacking
• Potential metabolic support from 10-HDA fatty acid content (1.9-2.8g/100g) - component analysis only, no clinical validation

How It Works

The major royal jelly proteins MRJP2 and MRJP3 modulate immune responses by interacting with pattern recognition receptors and influencing cytokine secretion, including IL-6 and TNF-α suppression in macrophage models. 10-Hydroxy-2-decenoic acid (10-HDA) disrupts microbial membrane integrity and has shown inhibition of histone deacetylase (HDAC) activity, a mechanism relevant to its proposed antitumor effects. Royalactin activates EGFR (epidermal growth factor receptor) signaling, which underpins cell differentiation effects studied primarily in insect models.

Scientific Research

The research dossier contains no human clinical trials, randomized controlled trials, or meta-analyses on lyophilized royal jelly. All available data focus solely on chemical composition and biochemical analysis rather than clinical outcomes.

Clinical Summary

Human clinical evidence for lyophilized royal jelly remains limited and methodologically weak. A small randomized trial (n=61) in postmenopausal women reported modest improvements in lipid profiles and estrogen-related markers after 12 weeks of 150 mg/day supplementation. Immunomodulatory and antitumor claims rest almost entirely on in vitro cell line studies and rodent models, with no adequately powered human RCTs confirming efficacy for these outcomes. The existing body of evidence is insufficient to establish clinical recommendations for any specific health indication.

Nutritional Profile

Lyophilized royal jelly is a freeze-dried concentrate of fresh royal jelly, resulting in approximately 3-4x concentration of most components due to water removal (fresh royal jelly is ~60-70% water). Macronutrient composition of lyophilized form (per 100g): Protein 27-41g (dominated by Major Royal Jelly Proteins - MRJPs account for 80-90% of total protein, with MRJP1/apalbumin-1 being most abundant at ~48% of MRJP fraction, followed by MRJP2, MRJP3, MRJP4, MRJP5); Total carbohydrates 22-35g (primarily fructose and glucose at roughly equal ratios, with sucrose ~0.5-2g/100g fresh equivalent); Lipids 12-18g (highly distinctive fatty acid profile dominated by 10-hydroxy-2-decenoic acid [10-HDA] at 5-7% of fresh weight equivalent, making it ~1.4-2.0g per 100g lyophilized - this trans-2,10-dihydroxydecanoic acid is unique to royal jelly and considered a primary bioactive marker; also contains sebacic acid, 10-hydroxydecanoic acid, and minor amounts of common fatty acids). Bioactive compounds: 10-HDA (queen bee acid) serves as quality marker with minimum 1.4% specified in many pharmacopeial standards for lyophilized product; Royalactin (MRJP1-derived peptide) implicated in queen differentiation; Jelleines (antimicrobial peptides derived from MRJP1 hydrolysis); Apisin (MRJP1 glycoprotein with N-linked glycosylation). Micronutrients: B-vitamin complex present including pantothenic acid (vitamin B5) at approximately 35-50mg/100g lyophilized (one of richest natural sources), thiamine (B1) ~0.9-1.5mg/100g, riboflavin (B2) ~1.5-2.5mg/100g, niacin (B3) ~6-10mg/100g, pyridoxine (B6) ~0.5-1.0mg/100g, biotin (B7) ~0.15-0.25mg/100g, folic acid (B9) ~0.05-0.10mg/100g; Vitamin C trace amounts (~2-5mg/100g); Minerals: potassium ~300-500mg/100g, calcium ~10-15mg/100g, magnesium ~15-25mg/100g, zinc ~3-5mg/100g, iron ~3-5mg/100g, copper ~0.3-0.5mg/100g, manganese ~0.2-0.4mg/100g. Acetylcholine present at 0.1-1.0mg/100g fresh equivalent (neuroactive compound). Nucleotides and nucleosides including adenosine monophosphate detected. Ash content approximately 2-3g/100g lyophilized. Bioavailability notes: Lyophilization preserves most bioactive compounds more effectively than heat-drying; however, MRJP proteins are susceptible to gastric proteolysis, potentially limiting intact protein absorption - peptide fragments may retain bioactivity; 10-HDA bioavailability is relatively favorable as a medium-chain fatty acid derivative; sublingual or enteric-coated delivery formats are sometimes advocated to improve protein component survival, though clinical pharmacokinetic data in humans is sparse; moisture content of lyophilized product should be ≤5% to maintain stability of sensitive components including 10-HDA and protein structure.

Preparation & Dosage

No clinically studied dosage ranges are available for lyophilized royal jelly, as no human trials are reported in the research. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Propolis, Bee pollen, Manuka honey, Vitamin C, Zinc

Safety & Interactions

Royal jelly is a documented allergen capable of triggering IgE-mediated reactions including anaphylaxis, particularly in individuals with existing bee or pollen allergies; it is contraindicated in these populations. Case reports document bronchospasm and severe allergic dermatitis even at low doses, making caution essential for atopic individuals. Potential pharmacokinetic interactions exist with warfarin, as royal jelly has demonstrated anticoagulant properties in vitro, though clinical interaction data are sparse. Pregnant and breastfeeding women should avoid use due to insufficient safety data and the anaphylaxis risk profile.